Canada markets closed

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0715+0.0019 (+2.76%)
At close: 02:12PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium

    LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in an industry panel and host one-on-one investor meetings at the virtual Canaccord Genuity Symposium on New Paradigms and

  • GlobeNewswire

    Small Pharma to Participate in November Investor and Healthcare Conferences

    LONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce its participation in the following upcoming conferences in November. Jefferies London Healthcare Conference, November 15-17 George Tziras, Chief Executive Officer of the Company, will participate in a fireside chat on November 16, 2022 at 4:25 p.

  • GlobeNewswire

    Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028

    SPL028 is the Company’s injectable deuterated DMT candidate with multi-layered IP protection The Phase I study aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration of SPL028 LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received appr